TR199900531A2 - Pirazolopirimidinler ve pirazolotriazinler. - Google Patents

Pirazolopirimidinler ve pirazolotriazinler.

Info

Publication number
TR199900531A2
TR199900531A2 TR1999/00531A TR9900531A TR199900531A2 TR 199900531 A2 TR199900531 A2 TR 199900531A2 TR 1999/00531 A TR1999/00531 A TR 1999/00531A TR 9900531 A TR9900531 A TR 9900531A TR 199900531 A2 TR199900531 A2 TR 199900531A2
Authority
TR
Turkey
Prior art keywords
disease
compounds
disorders
depressions
pirazolotriazines
Prior art date
Application number
TR1999/00531A
Other languages
English (en)
Other versions
TR199900531A3 (tr
Inventor
B�S Michael
Riemer Claus
Stadler Heinz
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of TR199900531A2 publication Critical patent/TR199900531A2/tr
Publication of TR199900531A3 publication Critical patent/TR199900531A3/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Bu bulus asagidaki genel formülleri havi pirazolopirmidinler ve pirazolotriazinler ve bunlarin farmasötik yönden kabul edilebilir tuzlari ile ilgilidir. Sasirtici bir sekilde, bu bilesikler 5HT-6 reseptörlerine karsi selektif bir affiniteye sahiptir. Buna uygun bir sekilde, bu bilisikler örnegin psikozlar, sizofreni, manik depresyonlar, depresyonlar, nörolojik bozukluklar, hafiza bozukluklari, Parkinson hastaligi, amiyotrofik lateral skleroz, Alzheimer hastaligi ve Huntington koreasi gibi merkezi sinir sistemi bozukluklarinin tedavisi ve önlenmesi için uygundur.
TR1999/00531A 1998-03-11 1999-03-11 Pirazolopirimidinler ve pirazolotriazinler. TR199900531A3 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98104346 1998-03-11

Publications (2)

Publication Number Publication Date
TR199900531A2 true TR199900531A2 (tr) 1999-10-21
TR199900531A3 TR199900531A3 (tr) 1999-10-21

Family

ID=8231568

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/00531A TR199900531A3 (tr) 1998-03-11 1999-03-11 Pirazolopirimidinler ve pirazolotriazinler.

Country Status (34)

Country Link
US (1) US6194410B1 (tr)
EP (1) EP0941994B1 (tr)
JP (1) JP3231288B2 (tr)
KR (1) KR100313181B1 (tr)
CN (1) CN1118468C (tr)
AR (1) AR016453A1 (tr)
AT (1) ATE240332T1 (tr)
AU (1) AU752408B2 (tr)
BR (1) BR9901095A (tr)
CA (1) CA2265095C (tr)
CZ (1) CZ291514B6 (tr)
DE (1) DE69907784T2 (tr)
DK (1) DK0941994T3 (tr)
ES (1) ES2198095T3 (tr)
HK (1) HK1023343A1 (tr)
HR (1) HRP990077B1 (tr)
HU (1) HUP9900589A1 (tr)
ID (1) ID23575A (tr)
IL (1) IL128869A (tr)
MA (1) MA26612A1 (tr)
MY (1) MY119536A (tr)
NO (1) NO312297B1 (tr)
NZ (1) NZ334526A (tr)
PE (1) PE20000337A1 (tr)
PL (1) PL331875A1 (tr)
PT (1) PT941994E (tr)
RU (1) RU2218340C2 (tr)
SG (1) SG78336A1 (tr)
SI (1) SI0941994T1 (tr)
TR (1) TR199900531A3 (tr)
TW (1) TW585865B (tr)
UY (1) UY25419A1 (tr)
YU (1) YU12099A (tr)
ZA (1) ZA991946B (tr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4331500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
DE19956791A1 (de) 1999-11-25 2001-05-31 Merck Patent Gmbh Neue Sulfonyloxazolamine
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
BR0208357A (pt) * 2001-03-13 2004-06-29 Bristol Myers Squibb Pharma Co Composto, composição farmacêutica, método de antagonização de um receptor de fator de liberação de corticotropina (crf), método de tratamento de disfunção, método de triagem de ligantes, método de detecção de receptores de crf, método de inibição da ligação de crf, artigo industrializado e usos do composto
EP1401813B1 (en) 2001-06-07 2007-02-07 F. Hoffman-la Roche AG New indole derivatives with 5-ht6 receptor affinity
CA2450245A1 (en) 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
WO2003013510A1 (en) * 2001-08-07 2003-02-20 Smithkline Beecham P.L.C. 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
RU2309157C2 (ru) * 2001-12-20 2007-10-27 Уайт Производные индолилалкиламина в качестве лигандов 5-гидрокситриптамина-6
US6642381B2 (en) * 2001-12-27 2003-11-04 Hoffman-La Roche Inc. Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
UA78999C2 (en) * 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
US6875771B2 (en) 2002-07-26 2005-04-05 Bristol-Myers Squibb Company Pyridopyrimidine derivatives as 5-HT6 antagonists
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
EP1592690A1 (en) * 2003-02-14 2005-11-09 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
KR20050115252A (ko) 2003-02-28 2005-12-07 데이진 화-마 가부시키가이샤 피라졸로[1,5-ａ]피리미딘 유도체
GB0305559D0 (en) * 2003-03-11 2003-04-16 Teijin Ltd Compounds
US20080287405A1 (en) * 2004-05-14 2008-11-20 Thannickal Victor J Compositions and Methods Relating to Protein Kinase Inhibitors
JP5584626B2 (ja) * 2008-01-24 2014-09-03 アンドレイ・アレクサンドロビッチ・イワシェンコ ２−アルキルアミノ−３−（アリールスルホニル）−シクロアルキル［ｅ又はｄ］ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体アンタゴニスト、その調製の方法及び使用
EP2248814A4 (en) 2008-01-24 2011-01-12 Alla Chem Llc SUBSTITUTED CYCLOALKAN [E AND D] PYRAZOLO [1,5-A] PYRIMIDINES / ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS AND PROCESS FOR THEIR PREPARATION AND THEIR USE
RU2369600C1 (ru) 2008-01-24 2009-10-10 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ5-HT6 РЕЦЕПТОРОВ, АКТИВНЫЙ КОМПОНЕНТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
WO2009093208A2 (ru) 2008-01-24 2009-07-30 Alla Chem, Llc ЗАМЕЩЕННЫЕ 2-AMИHO-3-CУЛЬФOHИЛ-ПИPAЗOЛO[1,5-a]ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
RU2384581C2 (ru) 2008-05-07 2010-03-20 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 2-АМИНО-3-СУЛЬФОНИЛ-ТЕТРАГИДРО-ПИРАЗОЛО[1,5-a]ПИРИДО-ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
CA2755968C (en) * 2008-10-06 2019-03-19 Andrey Alexandrovich Ivashchenko Substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines, serotonin 5-ht6 receptor antagonists and methods for the production and use thereof
AR074231A1 (es) 2008-11-27 2010-12-29 Boehringer Ingelheim Int Derivados de 6, 7, 8, 9-tetrahidro-5h-1, 4, 7, 10a-tetraaza-ciclohept[f]indeno, composiciones farmacéuticas que contienen estos compuestos, su uso en el agonismo del receptor 5-ht2c y procesos para prepararlos.
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
EP2640705A2 (en) 2010-11-15 2013-09-25 Katholieke Universiteit Leuven Novel antiviral compounds
RU2443697C1 (ru) 2010-12-21 2012-02-27 Александр Васильевич Иващенко Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения
JP6082397B2 (ja) 2011-09-30 2017-02-15 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． マクロ環状ｌｒｒｋ２キナーゼ阻害剤
NZ630721A (en) * 2012-03-09 2016-12-23 Lexicon Pharmaceuticals Inc Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法
BR112017005299A2 (pt) 2014-09-17 2017-12-12 Ipsen Pharma Sas inibidores de lrrk2 cinase macrocíclicos
CA2978170C (en) * 2015-03-09 2024-02-27 Aurigene Discovery Technologies Limited Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
WO2017052394A1 (en) * 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
AU2016348549B2 (en) 2015-11-02 2020-07-23 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
EA039102B1 (ru) 2016-11-02 2021-12-03 Янссен Фармацевтика Нв Соединения [1,2,4]триазоло[1,5-a]пиримидина в качестве ингибиторов pde2
CA3038913A1 (en) 2016-11-02 2018-05-11 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors
CN109923116B (zh) 2016-11-02 2022-12-06 詹森药业有限公司 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶衍生物
CN112142744A (zh) * 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368897A1 (en) 1987-07-31 1990-05-23 E.I. Du Pont De Nemours And Company Herbicidal sulfonamides
US4921527A (en) * 1987-07-31 1990-05-01 E. I. Du Pont De Nemours And Company Herbicidal sulfonamides
DE3825043A1 (de) 1988-07-20 1990-02-15 Schering Ag 3-methylsulfonyl-pyrazolo(1,5-a)pyrimidin-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, pflanzenwuchsregulierender und fungizider wirkung
US5571813A (en) * 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
AU7001396A (en) 1995-09-22 1997-04-09 Takeda Chemical Industries Ltd. Triazole compounds, their production and use
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
EP0946551A2 (en) 1996-12-19 1999-10-06 Smithkline Beecham Plc N-piperazin-1-ylphenyl-benzamide derivatives
NZ501258A (en) 1997-07-11 2001-07-27 Smithkline Beecham P Benzenesulfonamide compounds with 5HT6 receptor antagonist activity for treating anxiety and/or depression

Also Published As

Publication number Publication date
HU9900589D0 (en) 1999-05-28
PT941994E (pt) 2003-09-30
IL128869A0 (en) 2000-01-31
IL128869A (en) 2003-09-17
CZ291514B6 (cs) 2003-03-12
TW585865B (en) 2004-05-01
NO991150D0 (no) 1999-03-10
CZ82599A3 (cs) 1999-09-15
NO991150L (no) 1999-09-13
PL331875A1 (en) 1999-09-13
NZ334526A (en) 2000-07-28
ES2198095T3 (es) 2004-01-16
AU2038399A (en) 1999-09-23
AU752408B2 (en) 2002-09-19
UY25419A1 (es) 2001-11-30
MY119536A (en) 2005-06-30
DE69907784T2 (de) 2004-03-25
ATE240332T1 (de) 2003-05-15
US6194410B1 (en) 2001-02-27
YU12099A (sh) 2000-10-30
SI0941994T1 (en) 2003-10-31
EP0941994B1 (en) 2003-05-14
DE69907784D1 (de) 2003-06-18
PE20000337A1 (es) 2000-05-13
DK0941994T3 (da) 2003-09-08
AR016453A1 (es) 2001-07-04
CN1118468C (zh) 2003-08-20
EP0941994A1 (en) 1999-09-15
CA2265095A1 (en) 1999-09-11
RU2218340C2 (ru) 2003-12-10
NO312297B1 (no) 2002-04-22
MA26612A1 (fr) 2004-12-20
CA2265095C (en) 2008-07-22
HRP990077B1 (en) 2003-08-31
HRP990077A2 (en) 2000-02-29
JP2000186090A (ja) 2000-07-04
CN1236780A (zh) 1999-12-01
HUP9900589A1 (hu) 2000-03-28
ID23575A (id) 2000-05-04
HK1023343A1 (en) 2000-09-08
ZA991946B (en) 1999-09-13
KR19990077741A (ko) 1999-10-25
BR9901095A (pt) 2000-05-02
SG78336A1 (en) 2001-02-20
KR100313181B1 (ko) 2001-11-05
TR199900531A3 (tr) 1999-10-21
JP3231288B2 (ja) 2001-11-19

Similar Documents

Publication Publication Date Title
TR199900531A2 (tr) Pirazolopirimidinler ve pirazolotriazinler.
WO2001029012A3 (en) Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
TWI265928B (en) A61k 31/4025 200601 a i htw a61p 25/00 200601 a n htw
WO1999026927A3 (en) Metabotropic glutamate receptor antagonists for treating central nervous system diseases
BG102324A (en) Imidazole derivatives with affinity for the activity of alpha 2 receptors
CA2381819A1 (en) New benzimidazolone derivatives having mixed serotonine and dopamine receptors affinity
IL146871A0 (en) Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
ES2178676T3 (es) Compuestos de pirimidina substituidos y su empleo.
BG104278A (en) Methods and intermediate compounds for the preparation of anti-cancer compounds
HK1082728A1 (en) Azabicyclo derivatives as muscarinic receptor antagonists
AU2003208711A1 (en) 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders
TR199800027T1 (tr) Difenilmetilen piperidin türevleri.
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
AU4038000A (en) 4-substituted quinoline derivatives as gaba receptor ligands
BG105731A (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
MY133390A (en) Azabicyclic 5ht1 receptor ligands
AP2002002420A0 (en) Fused pyrrolecarboxamides: gaba brain receptor ligands.
WO2001007434A3 (de) Indolderivate und deren verwendung als 5ht2a liganden
NZ331769A (en) Indolomorphinan derivative and agent for curing and preventing cerebral disorder
ECSP992879A (es) Pirazolopirimidinas y pirazolotriazinas
ES2103237A1 (es) Nuevo compuesto derivado del cromeno
BR9900024A (pt) Biciclo[3.1.0]hexanos e compostos relacionados.
CA2249240A1 (en) Indolomorphinan derivative and agent for curing and preventing cerebral disorder
ECSP003715A (es) Derivados de benzodiazepin
MX9705390A (es) Uso de los 3,4-difenil-cromanos para la fabricacion de una composicion farmaceutica para el tratamiento o profilaxis de desordenes degenerativos cerebrales.